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We recently demonstrated that the secreted aspartyl proteinases (Saps), Sap2 and Sap6, of Candida albicans have the potential to
induce the canonical activation of the NLRP3 inflammasome, leading to the secretion of interleukin-1 (IL-1) and IL-18 via
caspase-1 activation. We also observed that the activation of caspase-1 is partially independent from the NLRP3 activation path-
way. In this study, we examined whether Sap2 and Sap6 are also able to activate the noncanonical inflammasome pathway in mu-
rine macrophages. Our data show that both Sap2 and Sap6 can activate caspase-11 through type I interferon (IFN) production.
Caspase-11 cooperates to activate caspase-1, with a subsequent increase of IL-1 secretion. Endocytosis and internalization of
Saps are required for the induction of type I IFN production, which is essential for induction of noncanonical inflammasome
activation. Our study indicates a sophisticated interplay between caspase-1 and caspase-11 that connects the canonical and non-
canonical pathways of inflammasome activation in response to C. albicans Saps.
Only a few Candida species are known as normally harmlesscommensals in the gastrointestinal, genitourinary, or oro-
pharyngeal tract of most healthy individuals, but these can also
cause superficial or systemic infections (1, 2). In fact, Candida
species are the fourth most common cause of hospital-acquired
systemic infections associated with a mortality rate of up to 50%
(3). The leading Candida species, which causes more than 50% of
all cases of candidiasis, is Candida albicans.
C. albicans is equipped with an arsenal of fitness and virulence
attributes which are crucial for causing infections (4). Morpho-
logical plasticity is key to the shift ofC. albicans from commensal-
ism to pathogenicity and includes the yeast-to-hypha transition
and the production of pseudohyphae (filamentous forms). While
pseudohyphae consist of elongated ellipsoidal cells with constric-
tions at the septa, true hyphae lack constrictions at the septa
and express a distinct set of hypha-associated genes (5, 6). Other
morphologies include white/opaque switching and chlamy-
dospores (4).
Thismorphological flexibility greatly contributes to the patho-
genesis of candidiasis, and the different morphological forms are
believed to play different roles at the various stages of infection,
including recognition by immune cells, adherence tomucosal sur-
faces, invasion and tissue damage, and escape from immune sys-
tem surveillance (7, 8). Additional important virulence factors
produced by C. albicans are the secreted aspartyl proteinases
(Saps). These enzymes are encoded by a family of 10 SAP genes
that have been extensively studied as key virulence determinants
of C. albicans (1). Of note, Sap2 is the most abundant protease
expressed by yeast cells in medium with protein as the sole source
of nitrogen; expression of Sap1 and Sap3 has been associated with
white/opaque switching, while Sap4 to Sap6 are hypha specific
(1). Similar proteases are produced by other pathogenic Candida
species, including C. parapsilosis and C. tropicalis (but not C.
glabrata) (9, 10) and contribute to the virulence potential of these
fungi.
We previously reported that Sap1, Sap2, Sap3, and Sap6 show
different abilities to induce the secretion of proinflammatory cy-
tokines by human monocytes. In particular Sap1, Sap2, and Sap6
were able to induce a great amount of cytokines, such as interleu-
kin-1 (IL-1), tumor necrosis factor alpha (TNF-), and IL-6,
by human monocytes, suggesting that Saps contribute to the
pathogenesis of candidiasis by activating the innate immune sys-
tem (11). We also demonstrated that the secretion of IL-1 and
IL-18 is greatlymediated by the canonical activation of theNLRP3
inflammasome (12). NLRP3 influences an innate immune re-
sponse by forming an intracellular multimolecular complex,
called the inflammasome, which leads to upregulation of IL-1
and IL-18 (13). A variety of pathogen- and host-derived “danger”
signals activate the NLRP3 inflammasome, including whole
pathogens, pathogen-associated molecular patterns (PAMPs),
other pathogen-associated molecules (e.g., bacterial pore-form-
ing toxins), host-derived indicators of cellular damage (danger-
associated molecular patterns, or DAMPs), and environmental
irritants. Upon activation, NLRP3, via the adaptor protein ASC,
induces caspase-1 activation, which cleaves pro-IL-1 and pro-
IL-18 into biologically active cytokines (13, 14).
Our own data suggest that Sap2 and Sap6 proteins trigger
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IL-1 production through inflammasome activation (11, 12).
This occurs via NLRP3 and caspase-1 activation, which in turn
cleaves pro-IL-1 into secreted bioactive IL-1. Interleukin-1
production was monitored in monocytes, in monocyte-derived
macrophages, and in dendritic cells after Sap stimulation (12).
Inflammasome activation required Sap internalization via a clath-
rin-dependent mechanism, intracellular induction of K efflux,
and reactive oxygen species (ROS) production (12). Of note, we
observed that silencing of NLRP3 did not lead to complete inhi-
bition of IL-1 secretion. Residual NLRP3 or additional activities
could contribute to production of the remaining IL-1, which is
considerable (about 20%), and we speculate that these mecha-
nisms contribute to the full activation and IL-1 production ob-
served.
In this study, we examined whether Sap2 and Sap6 have the
capacity to activate an additional noncanonical inflammasome
pathway (15, 16) that finally leads to innate immune cell activa-
tion.
MATERIALS AND METHODS
Aspartyl proteinase production. Recombinant C. albicans aspartyl pro-
teinases 2 and 6 (Sap2 and Sap6) were expressed as recombinant proteins
using Pichia pastoris clones (17); the proteins were purified and tested
negative for endotoxin contamination in a Limulus assay (E-Toxate;
Sigma) with a sensitivity of 10 pg/ml of Escherichia coli lipopolysaccharide
(LPS) (11).
Mice. Female, 6- to 8-week-old, inbred C57BL/6 mice were obtained
by Harlan Nossan Laboratories, Milan, Italy, and housed in the animal
facility of the University of Perugia (authorization number 34/2003A).
Ethics statement.The procedures involving the animals and their care
were conducted in conformity with national and international laws and
policies. All animal experiments were performed in agreement with EU
Directive 2010/63, the European Convention for the Protection of Verte-
brate Animals used for Experimental and other Scientific Purposes, and
National Law 116/92. The protocol was approved by Perugia University
Ethics Committee for animal care and use, permit number 149/2009-B.
Cells.Themurinemacrophage cell line RAW264.7was obtained from
the ATCC. Cells weremaintained inDulbecco’smodified Eagle’smedium
(DMEM) with L-glutamine supplemented with 10% fetal calf serum
(FCS) and antibiotics (complete medium) (all from EuroClone) at 37°C
in 5% CO2. Peritoneal murine macrophages (PM) were collected 4 days
after the intraperitoneal injection of 0.5 ml of endotoxin-free 10% thio-
glycolate solution (Difco) (18).
Western blot analysis. RAW 264.7 macrophages (5 106/ml) were
pretreated in complete medium in the presence or absence of a selec-
tive inhibitor of caspase-11 (IC-11), wedelolactone (40 M; Santa
Cruz Biotechnology) (19), or a neutralizing monoclonal antibody
(MAb) to type I interferon (IFN) receptor (IFNAR1) (0.5 g/ml; Mil-
lipore) (20) for 1 h, or chlorpromazine (10g/ml; Sigma) for 30min at
37°C in 5% CO2. Cells were then stimulated in the presence or absence
of 10g/ml LPS plus 5mMATP (LPS-ATP) (both from Sigma) or with
Sap2 or Sap6 (each, 20 g/ml) (11) for 30 min, 2, or 4 h at 37°C in 5%
CO2. To simultaneously stop the cultures, the stimuli were added
starting from 4 h to 30 min.
After incubation, cells were washed and lysed with mammalian pro-
tein extraction reagent in the presence of protease and phosphatase inhib-
itors (all from Pierce). Protein concentrations were determined with a
bicinchoninic acid (BCA) protein assay reagent kit (Pierce). The lysates
(60 g) were separated by sodium dodecyl sulfate–10% PAGE and trans-
ferred to a nitrocellulose membrane (Pierce) for 1 h at 100 V in a blotting
system (Bio-Rad). The membranes were incubated overnight with poly-
clonal antibodies (Abs) to caspase-11 (p20) (rabbit), caspase-1 (p10)
(goat), and IL-1 (p17) (goat) (all at a dilution 1/200; Santa Cruz),
NLRP3 (p117) (rabbit) (5g/ml; Imgenex), and caspase-8 (p18) (mouse)
(dilution of 1/1,000; Cell signaling) in blocking buffer. Detection was
achieved with the appropriate secondary Ab coupled to horseradish per-
oxidase (HRP), followed by a chemiluminescence trial kit (Chemicon
International). Immunoblotting with rabbit polyclonal Ab to actin (p43)
(dilution, 1/200; Santa Cruz) was used as an internal loading control.
Immunoreactive bands were visualized by a ChemiDoc instrument (Bio-
Rad). A quantitative analysis of the region of interest was performed using
the program Fiji Is Just ImageJ.
Flow cytometry analysis.RAW264.7macrophages (1 106/ml)were
pretreated in complete medium in the presence or absence of IC-11 (40
M) (19) for 1 h at 37°C in 5% CO2 and then stimulated in the presence
or absence of LPS (10 g/ml) plus ATP (5 mM) or with Sap2 or Sap6
(each, 20 g/ml) for 2 h at 37°C in 5% CO2. After incubation, cells were
fixed with 1.5% formalin for 10 min at room temperature (RT), washed,
and permeabilized with absolute methanol (500 l/106 cells) for 10 min
on ice and incubated with Ab to caspase-11 (p20) (rabbit) (dilution, 1/50;
Santa Cruz) for 20 min on ice, followed by Cy3-labeled conjugated affin-
ity-purified secondaryAb (dilution, 1/250; Chemicon International) (21),
and analyzed with a FACSCalibur flow cytometer (BD Biosciences). Au-
tofluorescence was assessed using untreated cells. Control staining of cells
with an irrelevant Ab was used to obtain background fluorescence values.
Cytokine production. Peritonealmurinemacrophages (PM) or RAW
264.7 macrophages (both, 5 106 cells/ml) were pretreated in complete
medium in the presence or absence of IC-11 (40 M) (19) or a neutraliz-
ing MAb to IFNAR1 (0.5 g/ml) (Millipore) (20) for 1 h or with chlor-
promazine (10 g/ml) for 30 min at 37°C in 5% CO2. Cells were then
stimulated in the presence or absence of LPS (10g/ml) plus ATP (5mM)
orwith Sap2 or Sap6 (each, 20g/ml) for 2, 18, or 48 h at 37°C in 5%CO2.
After incubation, the supernatants were collected and tested for IFN-,
IL-1, and IL-18 levels by specific enzyme-linked immunosorbent assays
(ELISAs; eBioscience). Cytokine titers were calculated relative to standard
curves.
Statistical analysis. The results reported in the bar graphs are the
means  standard errors of the means (SEM) from triplicate samples of
three to five different experiments. Quantitative variables were tested for
normal distribution and compared by means of a Student’s t test. A P
value of0.05 was considered significant.
RESULTS
Saps induce caspase-11 activation. Recently, we demonstrated
that Sap2 and Sap6 are able to induce NLRP3 inflammasome ac-
tivation that leads to subsequent cleavage of procaspase-1 into
caspase-1 and cleavage of pro-IL-1 into IL-1 (12). Silencing
NLRP3 leads to decreased production of IL-1 but not to a com-
plete blockade. Hence, we investigated whether possible addi-
tional mechanisms that support canonical inflammasome activa-
tion are involved.
Recent studies reported that caspase-11 is a regulator of
caspase-1 activation in response to enteric bacteria (22). Thus, we
first analyzed whether selected Saps induce caspase-11 activation.
To this end, cells of the murine macrophage cell line RAW 264.7
were treated for 30 min, 2, and 4 h with LPS-ATP as a positive
control or with Sap2 or Sap6 (each, 20 g/ml) in the presence or
absence of a selective inhibitor of caspase-11 (IC-11) at a concen-
tration of 40 M (19). This dose of Saps was previously found to
be the optimal dose to induce IL-1 production (11). The results
showed that Sap2 induces caspase-11 activation at 2 and 4 h post-
treatment, while Sap6 induces significant activation of caspase-11
after 2 h and that this level decreases in 4 h. LPS-ATP induced a
greater amount of caspase-11 activation after 2 and 4 h. Of note,
no activation of caspase-11 was observed within 30 min of incu-
bation under all conditions. Treatment of cells with IC-11 mark-
edly reduced Sap-induced activation of caspase-11 (Fig. 1A).
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The activation of caspase-11 was also assessed by cytofluoro-
metric analysis, and the results clearly confirmed that Sap2 and
Sap6 stimulation resulted in activation of caspase-11 within 2 h of
incubation and that IC-11 was able to downgrade this activation
(Fig. 1B).
Involvement of caspase-11 in Sap-induced IL-1 produc-
tion. To examine whether caspase-11 influences the NLRP3 in-
flammasome, cells were treated with Sap2 and Sap6 in the pres-
ence or absence of IC-11, and the expression of NLRP3 was
evaluated. The results shown in Fig. 2A indicate that Sap2 and
Sap6 activate NLRP3 already after 30 min of stimulation and that
this effect persists until 4 h. The inhibitor of caspase-11 does not
modify the activation of Sap-inducedNLRP3under any condition
investigated (Fig. 2A).
Additional experiments were performed to evaluate whether the
activation of caspase-11 influences caspase-1 activation. Sap2
and Sap6 increased cleavage of caspase-1 with different kinet-
ics. In particular, maximum activation of caspase-1 was ob-
served after 4 h of treatment with Sap2, while Sap6 induced the
optimal stimulation of caspase-1 after 2 h. Regarding the stim-
ulation with Sap2, treatment with IC-11 produced a drastic
decrease of caspase-1 activation at 4 h posttreatment while the
addition of IC-11 clearly inhibited caspase-1 activation at 2 and
4 h of incubation in response to Sap6. This inhibition was
substantial even after 4 h, when the Sap6-induced activation of
caspase-1 declined over time, suggesting that the modest acti-
vation of caspase-11 is indeed still able to regulate caspase-1
(Fig. 2B). Notably, pro-IL-1 was not cleaved after 2 h of stim-
ulation with Sap2 but was clearly cleaved after 4 h. At this time,
the addition of IC-11 drastically reduced the amount of cleaved
IL-1. When the cells were stimulated with Sap6, treatment
with IC-11 produced an inhibition of Sap6-induced IL-1
cleavage after 2 and 4 h (Fig. 3A). As previously demonstrated,
IL-1 and IL-18 were secreted via NLRP3 activation (12); as a
consequence, the production of these cytokines was tested in
the presence or absence of IC-11. RAW 264.7 macrophages
were stimulated with LPS-ATP or with Sap2 or Sap6 in the
presence or absence of IC-11. The results reported in Fig. 3B
show that both Saps induced the production of large amounts
of IL-1 and IL-18 in culture supernatants after 48 h of treat-
ment and that IC-11 drastically reduced the production of the
two cytokines (Fig. 3B). Similar results were obtained when
peritoneal murine macrophages (PM) were used (Fig. 3C).
Again, addition of IC-11 caused a strong inhibition of Sap-
FIG 1 Caspase-11 activation. (A) RAW 264.7 macrophages (5 106/ml) were pretreated for 1 h in the presence or absence of IC-11 (40M) and then cultured
for 30 min, 2, or 4 h in the presence or absence (not stimulated, NS) of LPS (10 g/ml) plus ATP (5 mM) or with Sap2 or Sap6 (each, 20 g/ml) in complete
medium at 37°C in 5%CO2. After incubation cell lysates were subjected toWestern blotting. Membranes were incubated with Abs to caspase-11 (p20) and actin
(p43). Bands of one experiment of five with similar results are shown for caspase-11 (left panel); caspase-11 (right panel) was normalized against actin. Error bars
denote SEM. *, P 0.05, for results from LPS-ATP- or Sap-treated cells versus those from untreated (NS) cells; #, P 0.05, for results from IC-11-treated cells
(with LPS-ATP or Saps) versus those from IC-11-untreated cells (LPS-ATP or Saps alone). (B) RAW264.7macrophages (1 106/ml) were cultured as described
for panel A. After 2 h of stimulation, intracellular staining of cells was performed using caspase-11 (p20)Ab, followed byCy3-labeled secondaryAb, and cells were
analyzed by a FACSCalibur flow cytometer. Representative FACSCalibur histograms show the mean of fluorescence intensity of one experiment of three with
similar results.
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induced IL-1 and IL-18 production (Fig. 3C). The abrogation
of IL-1 production mediated by IC-11 evidenced in PM sug-
gests that these cells are more susceptible to IC-11 than RAW
264.7 macrophages. Alternatively, secreted IL-1 is more
promptly reutilized by PM than by RAW 264.7 macrophages,
particularly considering that the incubation time was 48 h.
Regulation of caspase-11 activation by Sap-induced type I
interferon. It has been reported that caspase-11 may be activated
by type I interferon (IFN) (also known as IFN-). Therefore, we
analyzed whether Sap2 and Sap6 are able to induce IFN- release.
The results documented in Fig. 4A show that both Saps are able to
induce significant levels of IFN- after 2 h of incubation (Fig. 4A).
This effect was also evident after 18 h of incubation (data not
shown). Since we have been able to demonstrate that uptake of
Sap2 and Sap6 is inhibited by the clathrin-dependent endocytosis
inhibitor chlorpromazine (12), we evaluated whether chlorprom-
azine treatment would affect Sap-induced IFN- production.Our
results show that pretreatment with chlorpromazine significantly
inhibited Sap-induced IFN- production (Fig. 4A).
Next, the involvement of IFN- in the activation of caspase-11
was determined. The cells were treated in the presence or absence
of MAb to IFN- receptor 1 (IFNAR1), and the activation of
caspase-11 was determined. The results shown in Fig. 4B indicate
that caspase-11 activation is drastically reduced by blocking
IFNAR1 on RAW 264.7 macrophages.
Moreover, to verify whether the treatment with MAb to
IFNAR1 also influenced the production of IL-1 and IL-18, cells
were pretreated with MAb to IFNAR1 and stimulated with Saps
for 48 h. The results show that, by blocking IFNAR1, Sap-induced
production of both cytokines was significantly decreased (Fig.
4C). Moreover, we evaluated whether chlorpromazine treatment
could affect Sap-induced caspase-11 activation.Our results clearly
demonstrate that blocking endocytosis drastically reduced Sap-
induced caspase-11 activation (Fig. 4D).
FIG 2 NLRP3 and caspase-1 activation. RAW 264.7 macrophages (5 106/ml) were pretreated for 1 h in the presence or absence of IC-11 (40 M) and then
cultured for 30 min, 2, or 4 h in the presence or absence (NS) of LPS (10 g/ml) plus ATP (5 mM) or with Sap2 or Sap6 (each, 20 g/ml) in complete medium
at 37°C in 5%CO2. After incubation cell lysates were subjected toWestern blotting.Membranes were incubated with Abs toNLRP3 (p117), caspase-1 (p10), and
actin (p43). Bands of one experiment of five with similar results are shown for NLRP3 (A, left panel) and caspase-1 (B, left panel). NLRP3 (A, right panel) and
caspase-1 (B, right panel) amounts were normalized against those of actin. Error bars denote SEM. *, P 0.05, for results from LPS-ATP- or Sap-treated cells
versus those fromuntreated (NS) cells; #,P 0.05, for results from IC-11-treated cells (with LPS-ATPor Saps) versus those from IC-11-untreated cells (LPS-ATP
or Saps alone).
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DISCUSSION
The noncanonical inflammasome pathway is usually activated by
infection with Gram-negative bacteria, and the activation of this
pathway seems to be related to the presence of LPS and, in partic-
ular, to the toxic part of LPS, the lipid A (14, 22, 23). More re-
cently, it has been observed that selected Gram-positive bacterial
pathogens, such as Streptococcus pneumoniae, also induce the pro-
duction of type I IFN by host cells and that type I IFN regulates
FIG 3 IL-1 activation and cytokine production. (A) RAW264.7macrophages (5 106/ml) were pretreated for 1 h in the presence or absence of IC-11 (40M)
and then cultured for 2 or 4 h in the presence or absence (NS) of LPS (10 g/ml) plus ATP (5 mM) or with Sap2 or Sap6 (each, 20 g/ml) in complete medium
at 37°C in 5%CO2. After incubation, cell lysates were subjected toWestern blotting. Membranes were incubated with Abs to IL-1 (p17) and actin (p43). Bands
of one experiment of five with similar results are shown (left panel); IL-1 was normalized against actin (right panel). Error bars denote SEM. *, P 0.05, for
results fromLPS-ATP- or Sap-treated cells versus those fromuntreated (NS) cells; #, P 0.05, for results from IC-11-treated cells (with LPS-ATP or Saps) versus
those from IC-11-untreated cells (LPS-ATP or Saps alone). (B and C) RAW264.7macrophages or PM (both, 5 106/ml) were pretreated for 1 h in the presence
or absence of IC-11 (40M)and then cultured for 48 h in the presence or absence (NS) of LPS (10g/ml) plusATP (5mM)orwith Sap2 or Sap6 (each, 20g/ml)
in completemedium at 37°C in 5%CO2. After incubation, IL-1 and IL-18 levels were evaluated in culture supernatants using specific ELISAs. Error bars denote
SEM of triplicate samples of three experiments. *, P 0.05, for results from LPS-ATP-treated or Sap-treated cells versus those from untreated (NS) cells; #, P
0.05, for results from IC-11-treated cells (with LPS-ATP or Saps) versus those from IC-11-untreated cells (LPS-ATP or Saps alone).
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FIG 4 Neutralizing antibody to IFNAR1 and chlorpromazine block Sap-mediated caspase-11 activation. (A) RAW 264.7 macrophages (5  106/ml) were
pretreated for 30 min in the presence or absence (NS) of chlorpromazine (10 g/ml) and then incubated for 2 h with LPS (10 g/ml) plus ATP (5 mM) or with
Sap2 or Sap6 (each, 20 g/ml) in complete medium at 37°C in 5% CO2. After incubation culture supernatants were collected and tested for IFN- production.
Error bars denote SEM of triplicate samples of three experiments. *, P 0.05, for results from LPS-ATP-treated or Sap-treated cells versus those from untreated
(NS) cells; #,P 0.05, for results fromchlorpromazine-treated cells (with LPS-ATPor Saps) versus those fromchlorpromazine-untreated cells (LPS-ATPor Saps
alone). (B) RAW 264.7 macrophages (5 106/ml) were pretreated for 1 h in the presence or absence of MAb to IFNAR1 (0.5 g/ml) and then cultured for 2 h
in the presence or absence (NS) of LPS (10 g/ml) plus ATP (5 mM) or with Sap2 or Sap6 (each, 20 g/ml) in complete medium at 37°C in 5% CO2. After
incubation cell lysates were subjected to Western blotting. Membranes were incubated with Abs to caspase-11 (p20) and actin (p43). Bands of one experiment
of five with similar results are shown (upper panel). The amount of Caspase-11 was normalized against that of actin (lower panel). Error bars denote SEM. *, P
0.05, for results from LPS-ATP-treated or Sap-treated cells versus those from untreated (NS) cells; #, P 0.05, for results from anti-IFNAR1 treated cells (with
LPS-ATP or Saps) versus those from anti-IFNAR1-untreated cells (LPS-ATP or Saps alone). (C) RAW264.7macrophages (5 106/ml) were treated as described
above in complete medium at 37°C in 5% CO2. After 48 h of incubation, IL-1 and IL-18 levels were evaluated in culture supernatants using specific ELISAs.
Error bars denote SEM of triplicate samples of three experiments. *, P 0.05, for results from LPS-ATP-treated or Sap-treated cells versus those from untreated
(NS) cells; #, P  0.05, for results from anti IFNAR1-treated cells (with LPS-ATP or Saps) versus those from anti-IFNAR1-untreated cells (LPS-ATP or Saps
alone). (C) Cell lysates from the experiment described for panel A were subjected toWestern blotting. Membranes were incubated with Abs to caspase-11 (p20)
and actin (p43). Bands of one experiment of five with similar results are shown (left panel). The amount of caspase-11 was normalized against that of actin (right
panel). Error bars denote SEM. *, P 0.05, for results from LPS-ATP-treated or Sap-treated cells versus those from untreated (NS) cells; #, P 0.05, for results
from chlorpromazine-treated cells (with LPS-ATP or Saps) versus those from chlorpromazine-untreated cells (LPS-ATP or Saps alone).
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resistance and proinflammatory responses (24). Type I IFN sig-
naling was also required for activation of caspase-1, which is im-
portant for maturation and secretion of IL-18 (24).
Compelling evidence shows that caspase-11 activation occurs
in response to intracellular Gram-negative bacteria also in cells
lacking LPS receptors, such as Toll-like receptor 4 (TLR4), sug-
gesting that other LPS receptors are involved (25, 26). Therefore,
even though the signal pathway of activation that is triggered via
engagement of TLR4 is well described (27), alternative mecha-
nisms that involve noncanonical activation of the inflammasome
must be considered.
In this study, we demonstrate for the first time that secreted
virulence factors of C. albicans, members of the secreted aspartyl
proteinase (Sap) family, induce noncanonical activation of the
inflammasome. Indeed, both purified Sap2 and Sap6 induce
caspase-11 activation though with different kinetics. Cells express
caspase-11 in response to both Sap2 and Sap6, and this expression
is more prolonged in response to Sap2 than to Sap6. The activa-
tion of caspase-11 does not affect Sap-inducedNLRP3 expression,
but the selective inhibition of caspase-11 (19) results in a consis-
tent downregulation of caspase-1 activation. These results clearly
indicate that caspase-11 is involved in the activation of caspase-1,
consistent with the observation that maximum caspase-1 activa-
tion is related to the concurrent presence of activated caspase-11.
As a matter of fact, a trend of kinetic activation was an interplay
between caspase-1 and caspase-11. For instance, in response to
Sap2, the best stimulation of caspase-1 occurs after 4 h of stimu-
lation, and at the same time a substantial activation of caspase-11
is observed. The highest stimulation of caspase-1 in response to
Sap6 is observed after 2 h of stimulation, and at this time the
strongest stimulation of caspase-11 is evidenced. In agreement
with this hypothesis, a significant reduction of caspase-1 activa-
tion was manifested in the presence of caspase-11 inhibitor. In-
deed the activation of caspase-1 in response to Sap2 after 2 h of
treatment does not reflect the activation of IL-1. This could be
ascribed, at least in part, to the relative temporal difference in
activation of caspase-1 and production of pro-IL-1 that are
induced via different signal transduction pathways, as shown in
Fig. 5.
Moreover, a complete reduction of IC-11-induced caspase-1
activation after 4 h of Sap treatment correlated with a drastic re-
duction of IL-1 production, suggesting that in the late phase, in
contrast to the early phase, the activation of caspase-11 is neces-
sary for caspase-1 activation and for subsequent IL-1 secretion.
Nonetheless, caspase-11 is not necessarily required for Sap-
induced caspase-1 activation mediated by NLRP3; however,
caspase-11 plays a key role in potentiating and prolonging
caspase-1 activation via induction of type I IFN.
Therefore, caspase-11 markedly influences caspase-1 activa-
tion and the subsequent production of IL-1 and IL-18. This was
particularly evident for the IL-1 production by PM. Further-
more, the induction of caspase-11 is at least in part mediated by
type I IFN secreted in response to Sap2 and Sap6. This observation
is supported by the fact that the blockade of IFNAR1, before stim-
ulation with Saps, results in a drastic reduction of caspase-11 ac-
tivation.
In our previous study we observed that caspase-1 activation in
response to Sap2 was maximal after 1 h and then decreased,
whereas IL-1 activation in response to Sap6 was increased after 4
h. In this study, we observed that the Sap2-induced activation of
caspase-1 was evident at 30 min posttreatment and reached max-
imum levels after 4 h. Moreover, IL-1 activation in response to
Sap6 was evident just after 2 h and continued until 4 h. This ap-
parent discrepancy could be due to different cells and the experi-
mental setting used, such as different culture conditions including
cell concentrations and greater amounts of protein analyzed by
Western blotting.
Indeed, in contrast to our previous study, where freshly iso-
lated human monocytes were used, we analyzed a murine macro-
phage cell line in this study. These different experimental settings
FIG 5 Model of canonical and noncanonical Sap-induced inflammasome activation. Sap2 and Sap6 activate the NLRP3 inflammasome pathway through early
and late signals. Sap2 and Sap6 induce an early cascade of events (within 30 min), causing upstream NLRP3 inflammasome activation and downstream
caspase-1-mediated cytokine production (early signal). Sap endocytosis induces the translocation ofNF-	B (p50/p65) into the nucleus, leading to pro-IL-1 and
pro-IL-18 synthesis. Sap2 and Sap6 subsequently induce, through type I IFN production, caspase-11 activation (within 2 h) that cooperates with the NLRP3
inflammasome, triggering downstream caspase-1-mediated cytokine production (late signal).
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could also account for the lower cytokine production observed in
response to Saps. Given that caspase-8 could be involved in the
activation of the inflammasome, we also tested the activation of
caspase-8 in response to Saps. In our experimental system,
caspase-8 is not involved in Sap-induced inflammasome activa-
tion (data not shown).
We recently demonstrated that both Sap2 and Sap6 cause in-
creased production of IL- and IL-18 via canonical inflam-
masome activation (12) and that this occurs via activation of
caspase-1. We also observed that the activation of caspase-1 was
partially independent of the NLRP3 activation pathway. Indeed,
in this study we add new, important information by demonstrat-
ing that the increase in caspase-1 activation is supported and po-
tentiated by caspase-11. Of note, caspase-11 does not affect
NLRP3 expression, but it supports directly the activation of
caspase-1. A possible scenario could involve caspase-1 that is re-
cruited and activated early by NLRP3 (early signal, 30 min); sub-
sequently, the activation of caspase-1 is enhanced andmaintained
by the increased expression of caspase-11 (late signal, 2 h) (Fig. 5).
This scenario is supported by analyzing the kinetics of caspase-1
and caspase-11 expression. Caspase-1 activation is evident already
after 30 min of Sap stimulation, whereas the activation of
caspase-11 requires at least 2 h of stimulation. Notably, NLRP3 is
already highly activated after 30 min. Thus, NLRP3 and caspase-1
activation occurs concomitantly. The activation of caspase-11 is
observed later and is related to stimulation of type I IFN. This
process is summarized in Fig. 5. It has been reported that TLR4/
Trif-mediated type I IFN plays a pivotal role in caspase-11 activa-
tion (15). del Fresno et al. have recently reported that C. albicans
induces type I IFN in dendritic cells through aDectin-1-, Syk-, and
Card9-dependent pathway (28). In addition, other research
groups have shown that Ifnar
/
 mice are extremely resistant to
otherwise lethal Candida and Histoplasma infections (29, 30).
These studies demonstrated that type I IFN induces severe kidney
damage by promoting excessive recruitment and activation of in-
flammatory monocytes and neutrophils. However, other reports
suggest that type I IFN can be beneficial as part of the host immune
response to C. albicans (28, 31). Other studies related to sepsis
show that type I IFN plays a critical role in promoting lethal en-
dotoxemia (32, 33). Finally, many aspects of this pathway remain
unclear, and twomodels in which activation is triggered byGram-
negative bacteria have been suggested: one is receptor scaffold-
mediated activation and the other is related to auto-activation of
procaspase-11 (15).
In the first model, caspase-11 activation is induced by type I IFN
signaling, which in turn increases procaspase-11 expression via
IFNAR1 and induces the expression of an inducible receptor/activa-
tor of caspase-11 (15). The second possible mechanism is auto-acti-
vation of procaspase-11. Signaling through Trif and IFN regulatory
factor 3 (IRF3) induces expression of type I IFN, which induces pro-
caspase-11 that, via auto-activation, induces caspase-11 expression
(16).
In our experimental system, the activation of caspase-11 is re-
lated to release of type I IFN in response to Saps; it is noteworthy
that this is the first demonstration that distinct proteins, the Saps
of C. albicans, are able to induce type I IFN release. The mecha-
nism that leads to type I IFNproduction and caspase-11 activation
is unclear. We previously demonstrated that clathrin-dependent
endocytosis, likely associatedwith an intracellular danger signal, is
necessary for activating the canonical NLRP3 inflammasome by
Saps (12). Indeed Sap endocytosis and internalization are also
required for the induction of type I IFN that, in turn, interacts
with IFNAR1. This pathway leads to activation of procaspase-11.
Pyroptosis is a nonhomeostatic lytic model that shares some fea-
tures with caspase-independent necrotic cell death (22). Pyropto-
sis requires enzymatic activity of caspase-1 or caspase-11 (16, 34).
Caspase-1 has been involved in pyroptosis induction as well as in
processing IL-1 and IL-18, whereas caspase-11 is involved only
in pyroptosis induction (34). Therefore, the activity of caspase-11
in regulating IL-1 and IL-18 secretion is exclusively related to its
capacity to affect activation of caspase-1. Indeed, it has recently
been reported that caspase-11 mediates extracellular release of
IL-1 and IL-18 indirectly through regulation of the inflam-
masome and/or caspase-1 (34). In our experimental setting, we
demonstrate that there is no cross talk between NLRP3 and
caspase-11, but caspase-11 potentiates caspase-1 activation and,
as a consequence, the secretion of proinflammatory cytokines.
The activation of a noncanonical inflammasome exerted by
Saps opens a novel scenario in which not only microorganisms,
and particularly Gram-negative bacteria, participate in the activa-
tion of a noncanonical inflammasome but also distinct virulence
factors of the pathogenic fungus C. albicans can trigger this acti-
vation. The identification of this mechanism could also open
novel therapeutic strategies to dampen hyperinflammatory re-
sponses, which are characteristic attributes of a disease such as
vaginal candidiasis. Since it is known that Saps are secreted in large
amounts during vaginal candidiasis (35), our future studies will be
devoted to validating the role of Sap secretion in inducing the
noncanonical inflammasome during mucosal, in particular, vag-
inal, candidiasis in vivo.
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